VivoSeq
Oncology

Ovarian Neoplasms

14

Pipeline Programs↗

9

Active Trials↗

10

Companies Involved↗

Ovarian Neoplasms is an emerging landscape with 14 programs across 10 companies. The most active players are Glaxo Dba Glaxosmithkline, Merck & Co., GSK. 11 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

27/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Glaxo Dba Glaxosmithkline

1 program

Phase 2Merck & Co. logo

Merck & Co.

4 programs

Phase 3GSK logo

GSK

1 program

Phase 3A

Avyxa

1 program

Phase 3Teva logo

Teva

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

10 of 13 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody215%Antibody–drug conjugate18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 87% of 15 pipeline programs.

Analysis

Trial Status

9

clinical trials

Recruiting6 · 67%
Not yet recruiting3 · 33%

Clinical Trials

Trial Activity

9 trials

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer
Recruiting·GSK logoGSK·Phase 3·NCT07286266·450 enrolled
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07213791·241 enrolled
FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07213804·1,630 enrolled
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT07318558·900 enrolled
A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors
Recruiting·XXadcera Biopharmaceutical (Suzhou) Co., Ltd.·Preclinical·NCT06751329·280 enrolled
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
Recruiting·GSK logoGSK·Phase 2·NCT04641247·37 enrolled
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With or Without Bevacizumab in Comparison to Active Observation With or Without Bevacizumab as Maintenance Treatment in Participants With Newly Diagnosed FIGO Stage III/IV Non-Homologous Recombination Deficient Ovarian Cancer
Not yet recruiting·GSK logoGSK·Phase 3·NCT07694427·720 enrolled
A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-Sensitive Ovarian Cancer
Not yet recruiting·GSK logoGSK·Phase 3·NCT07684612·690 enrolled
The Role of Blood-Based Minimal Residual Disease in Patients With Advanced Epithelial Ovarian Cancer After 1st Line Therapy
Not yet recruiting·AAsan Medical Center·N/A·NCT07670962·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)